Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trend Setters and Range Riders -- Ignore unavailable to you. Want to Upgrade?

To: Susan G who wrote (3595)	11/2/2001 11:45:39 AM
From: Connor26	Respond to of 26752

BEAS going

To: Susan G who wrote (3595)	11/2/2001 11:46:55 AM
From: Connor26	Respond to of 26752

don't follow NOVN but it sure didn't sound to bad Novogyne's current quarter net revenues more than doubled to $28.5 million from $13.5 million due to increased sales of Vivelle-Dot(TM) and the addition of CombiPatch(R) in March 2001. Novogyne's selling, general and administrative expenses increased to $9.7 million for the current quarter from $5.1 million in the 2000 quarter, primarily due to the relaunch of CombiPatch and expansion of the Novogyne sales force. Novogyne amortized $1.5 million of CombiPatch acquisition cost during the current quarter. Novogyne's net income for the current quarter was $12.0 million, an 85% increase over the $6.5 million reported in the 2000 quarter.